(Q36736364)

16 August 2017

1 reference

title

Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours (English)

1 reference

16 August 2017

Edwina N Scott

1

1 reference

16 August 2017

Gerold Meinhardt

2

1 reference

16 August 2017

Christian Jacques

3

1 reference

16 August 2017

Dirk Laurent

4

1 reference

16 August 2017

Anne L Thomas

5

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Expert Opinion on Investigational Drugs

16 August 2017

1 reference

16 August 2017

16

1 reference

16 August 2017

3

1 reference

16 August 2017

367-379

1 reference

Tumor angiogenesis: therapeutic implications

16 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

Angiogenesis and its role in colorectal tumor and metastasis formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

Antivascular therapy of oral tongue squamous cell carcinoma with PTK787.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

Targeted therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

Sunitinib malate for the treatment of solid tumours: a review of current clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

Targeting angiogenesis with oral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

Why do cancers have high aerobic glycolysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.3.367

10.1517/13543784.16.3.367

21 January 2018

Identifiers

DOI

1 reference

release_5mh6iwldvnh6padzeuhg3qwy4y

16 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5mh6iwldvnh6padzeuhg3qwy4y

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference